Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others.

/EIN News/ -- Los Angeles, June 17, 2021 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis Pipeline: Drug Pipeline, Regulatory Events and Clinical Trials in the Spotlight| Insights by DelveInsight

The report offers the most up-to-date information on Axial Spondyloarthritis pipeline products being developed by notable companies such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, and UCB Biopharma, among others.

DelveInsight’s ‘Axial Spondyloarthritis (axSpA) Pipeline Insights’ report offers exhaustive coverage of the emerging therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. 

Some of the important takeaways from the Axial Spondyloarthritis Pipeline report:

• Axial Spondyloarthritis Pipeline report offers an extensive analysis of 30+ key players and 30+ key therapies.
• Axial Spondyloarthritis pipeline candidates are under evaluation in different stages of the clinical phase such as QX 002N, Jaktinib, SCB-808, FPP003, KIN-1901, Namilumab, ENIA11, and others expected to get launched in the foreseeable future. 
• Some of the key companies expanding the Axial Spondyloarthritis Pipeline are Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, FunPep Co Ltd., Kinevant Sciences, Izana Bioscience, Mycenax Biotech, UCB Biopharma, among others.
• DelveInsight estimates that the late-stage products Bimekizumab and Tofacitinib are expected to have a major impact on the Axial Spondyloarthritis treatment market.
• Therapies in development for axSpA focus on targets such as JAK/STAT, IL-17, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs are administered via oral, intravenous, subcutaneous, and topical routes.
• Tofacitinib, sold under the brand Xeljanz, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In November 2020, Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active Ankylosing Spondylitis (AS). 
• Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. It is in the phase 3 stage of development for the treatment of Axial Spondyloarthritis.

Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Axial Spondyloarthritis Emerging Therapies and Forecast 

The Axial Spondyloarthritis Pipeline reports lay down a thorough coverage of the ongoing clinical trials, collaborations taking place in the domain, recent happenings in the Axial Spondyloarthritis pipeline space, and growth prospects across the Axial Spondyloarthritis domain.

Axial Spondyloarthritis: Overview

Axial Spondyloarthritis is a chronic, inflammatory rheumatic disease that affects primarily the axial joints leading to severe pain, stiffness, and fatigue. It starts with an early inflammatory phase in which there is no structural damage in the sacroiliac joints (non-radiographic disease) progressing to later stages in which structural damage is visible on X‑ray scans of the sacroiliac joints as erosions, sclerosis, or bony bridges (radiographic disease; also known as Ankylosing Spondylitis).

Discover more about the disease, treatments, and pipeline therapies @ axSpA Pipeline Assessment 

Axial Spondyloarthritis Pipeline Drugs 

Drug	Company	Phase	MoA	RoA
QX 002N	Qyuns Therapeutics	Phase I	Interleukin-17 inhibitors	Subcutaneous
Jaktinib	Suzhou Zelgen Biopharmaceuticals	Phase II	Janus kinase 1,2,3 inhibitors	Oral
SCB-808	Clover Biopharmaceuticals	Phase III	Tumour necrosis factor inhibitors	Subcutaneous
FPP003	FunPep Co Ltd.	Preclinical	Immunostimulants	NA
KIN-1901	Kinevant Sciences	Phase I	Granulocyte macrophage colony stimulating factor antagonists	Subcutaneous
Namilumab	Izana Bioscience	Phase II	Granulocyte macrophage colony stimulating factor antagonists	Subcutaneous
ENIA11	Mycenax Biotech	Phase III	Tumour necrosis factor inhibitors	Subcutaneous
Bimekizumab	UCB Biopharma	Phase III	IL17A protein inhibitors; IL17F protein inhibitors	Intravenous; subcutaneous

Request for Sample to know more @ Axial Spondyloarthritis Pipeline Analysis, Key Companies, and Futuristic Trends 

Axial Spondyloarthritis Therapeutics Assessment 

The Axial Spondyloarthritis Pipeline report presents a kaleidoscopic view of the axSpA emerging novel therapies segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action.

By Product Type

• Mono
• Combination

By Stage

• Discovery 
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type 

• Monoclonal Antibody
• Peptide vaccine
• Interleukin
• Small molecule
• Recombinant fusion proteins

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Topical

By Mechanism of Action

• Tumour necrosis factor inhibitors
• Granulocyte-macrophage colony-stimulating factor antagonists
• Interleukin-17 inhibitors
• Janus kinase 1 inhibitors
• Immunostimulants
• IL17A protein inhibitors; IL17F protein inhibitors

By Targets

• Tumour necrosis factor
• Granulocyte-macrophage colony-stimulating factor
• Interleukin-17
• Janus kinase 1
• IL17A protein

For rich insights into merging therapies and assessment, visit Axial Spondyloarthritis Pipeline: Emerging Novel Therapies 

Scope of the Axial Spondyloarthritis Pipeline Report

Coverage: Global
Key Players: Izana Bioscience, UCB, Sun Pharma Global, Akeso Biopharma, Kinevant Sciences, Jiangsu Hengrui Medicine Co., Suzhou Zelgen Biopharmaceuticals, Clover Biopharmaceuticals, Mycenax Biotech, Boehringer Ingelheim, and Qyuns Therapeutics among others.
Key Axial Spondyloarthritis Pipeline Therapies: Namilumab , Bimekizumab, Tofacitinib, Tildrakizumab, AK-111, NDI 031232, Gimsilumab, QX002N, SHR-0302, Jaktinib, SCB-808, FPP003, KIN-1901, ENIA11, BI 730357, and QX002N  among others.

Discover more about the report offerings @ axSpA Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

1	Report Introduction
2	Executive Summary
3	Axial Spondyloarthritis Disease Overview
4	axSpA Pipeline Therapeutics Comparative Analysis
5	Axial Spondyloarthritis Therapeutic Assessment
6	Axial Spondyloarthritis – DelveInsight’s Analytical Perspective
7	In-depth Commercial Axial Spondyloarthritis Assessment
8	Axial Spondyloarthritis Collaboration Deals
9	Late Stage Axial Spondyloarthritis Products (Phase III)
10	Mid-Stage Axial Spondyloarthritis Products (Phase II)
11	Early Stage Axial Spondyloarthritis Products (Phase I)
12	Pre-clinical and Discovery Stage axSpA Products
13	Inactive Axial Spondyloarthritis Pipeline Products
14	Key Axial Spondyloarthritis Products
15	Unmet Needs
16	axSpA Market Drivers and Barriers
17	Future Perspectives and Conclusion
18	Analyst Views
19	Key Axial Spondyloarthritis Companies
20	Appendix

Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions 

Related Reports

Axial Spondyloarthritis Market
DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology, and Market Forecast-2030" report. 

Non-Radiographic Axial Spondyloarthritis Market
DelveInsight's "Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Market Insights, Epidemiology, and Market Forecast-2030" report.

Spondylolisthesis Market Insights
DelveInsight's “Spondylolisthesis Market Insights, Epidemiology, and Market Forecast-2030" report.

Ankylosing Spondylitis Market
DelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2030’ report.

Global Kinase Inhibitor In Autoimmune Diseases Market
DelveInsight’s ‘Global Kinase Inhibitor in Autoimmune Diseases Market Insights and Market Forecast – 2030’ report.

Adenosine Deaminase Severe Combined Immunodeficiency Market
DelveInsight's "Adenosine Deaminase-Severe Combined Immunodeficiency Market Insights, Epidemiology, and Market Forecast-2030" report.

Adult-Onset Still Disease Market
DelveInsight’s “Adult-onset Still’s Disease Market Insights, Epidemiology, and Market Forecast – 2030” report.

Browse through our posts 
ABSSSI Pipeline Analysis 
Parkinson's Disease Risk Factors
Wearable Healthcare Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

Contact Us
                    
                    Shruti Thakur 
                    
                    info@delveinsight.com 
                    
                    +1(919)321-6187 
                    
                    www.delveinsight.com